The development of Chinese medicine is included in the right to health, and the speed of industrial upgrading will continue to accelerate

Traditional Chinese medicine is a treasure of Chinese national culture.
In recent years, China has continuously increased its support for the cause and industry of Chinese medicine.
The operation of Chinese medicine has become increasingly prominent, and many places have entered a new stage of high-quality development of the Chinese medicine industry
.
China’s policy support for the Chinese medicine industry continues to increase.
For example, in 2016, the "Outline of the Strategic Plan for the Development of Traditional Chinese Medicine (2016-2030)" was released, and the development of Chinese medicine was upgraded to a national strategy; in July 2017, the "Chinese Medicine Law of the People's Republic of China" "Implementation, the inheritance, innovation and development of traditional Chinese medicine has since been guaranteed by the rule of law
.
In 2021, policies related to Chinese medicine will continue to be improved
.
For example, in February 2021, the "Notice on Several Policy Measures to Accelerate the Development of Traditional Chinese Medicine Features" clearly stated that long-term investment in the Chinese medicine industry should be increased
.
On May 12, 2021, high-level officials set the tone to vigorously develop traditional Chinese medicine, focus on interpreting the principles of traditional Chinese medicine with modern science, and take the road of integration of traditional Chinese and Western medicine
.
On September 9, 2021, the National Human Rights Action Plan (2021-2025) included the promotion of the development of Chinese medicine in the right to health, and proposed to adhere to the equal emphasis on Chinese and Western medicine and complement each other's advantages, and vigorously develop the cause of Chinese medicine
.
Driven by favorable policies, China's traditional Chinese medicine industry has developed rapidly
.
According to data from the National Bureau of Statistics, from 2016 to 2019, the average annual compound growth rate of the Chinese herbal medicine market turnover was 10.
38%, reaching 165.
3 billion yuan in 2019
.
It is estimated that in 2021, with China’s increased support for the Chinese medicine industry, the market turnover of Chinese medicinal materials may reach 194.
525 billion yuan
.
In addition, according to the China Commercial Industry Research Institute, China's traditional Chinese medicine pharmaceutical market will reach 75.
3 billion yuan in 2021, showing an upward trend
.
There are also data showing that from 2016 to 2020, the average annual compound growth rate of China's traditional Chinese medicine manufacturing market will reach 3.
6% or more, from 64 billion yuan to 73.
5 billion yuan
.
Industry analysts pointed out that with the support of many favorable policies and the background of placing Chinese medicine work in a more prominent position in various places, the inheritance and innovation of Chinese medicine has entered a new stage and embarked on a new journey.

.
For example, from the national level to the local level, the overall plan for the development of traditional Chinese medicine shows that the speed of innovation, research and development and industrial upgrading of Chinese medicine enterprises is accelerating and entering the golden period of development
.
Take Buchang Pharmaceuticals as an example.
Under the promotion of favorable policies, Buchang Pharmaceuticals focuses on patented Chinese patent medicines, is committed to the modernization of Chinese medicine, and gives full play to the important role of Chinese medicine in the field of "serious and chronic diseases" of cardiovascular and cerebrovascular diseases
.
Relying on its R&D advantages, it extends from proprietary Chinese medicines to biological medicines, chemical medicines and other fields, and has made breakthroughs in the promotion of mature varieties and the research and development of new types of drugs
.
Data show that in the first quarter of 2021, Buchang Pharmaceutical's research and development expenses increased by 62.
58% year-on-year to 78 million yuan; sales expenses fell 18.
78% year-on-year to 1.
651 billion yuan
.
This "one increase and one decrease" better reflects the transformation process of Buchang Pharmaceutical
.
With the implementation of policies to promote the development of the Chinese medicine industry by the country and localities, the Chinese medicine industry has achieved better development in recent years
.
However, some analysts pointed out that there are still many shortcomings and weaknesses in the inheritance and innovation of traditional Chinese medicine, such as insufficient total volume, shortage of talents, weak innovation ability, and lack of outstanding characteristics of traditional Chinese medicine
.
During the "14th Five-Year Plan" period, China still needs to continue to increase its support for related work
.
It is reported that Shandong Province recently issued the "Fourteenth Five-Year Plan for the Development of Traditional Chinese Medicine in Shandong Province".
According to the plan, Shandong will have Important measures have been deployed
.
Shandong Province will address the blockages, difficulties, and pain points in the development of traditional Chinese medicine in the province, and consult the pulse to alleviate the "stuck neck" problem in the development of traditional Chinese medicine
.